Gerald L. Ray & Associates’s GSK GSK Stock Holding History

Gerald L. Ray & Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$372K	Sell	7,334 -1,720	-19%	-$87.3K	0.05%	254
2017 Q2	$488K	Hold	9,054	–	–	0.06%	222
2017 Q1	$477K	Sell	9,054 -4,000	-31%	-$203K	0.07%	221
2016 Q4	$628K	Sell	13,054 -4,800	-27%	-$237K	0.09%	194
2016 Q3	$963K	Hold	17,854	–	–	0.14%	134
2016 Q2	$967K	Hold	17,854	–	–	0.15%	125
2016 Q1	$905K	Buy	17,854 +116	+0.7%	+$5.78K	0.15%	125
2015 Q4	$895K	Sell	17,738 -140	-0.8%	-$7.14K	0.14%	127
2015 Q3	$860K	Hold	17,878	–	–	0.14%	130
2015 Q2	$931K	Sell	17,878 -608	-3%	-$34.2K	0.14%	138
2015 Q1	$1.07M	Buy	18,486 +1,880	+11%	+$108K	0.16%	130
2014 Q4	$887K	Buy	16,606 +200	+1%	+$11.2K	0.14%	135
2014 Q3	$943K	Buy	16,406 +2,200	+15%	+$135K	0.15%	131
2014 Q2	$950K	Hold	14,206	–	–	0.16%	128
2014 Q1	$949K	Buy	14,206 +448	+3%	+$30.3K	0.17%	122
2013 Q4	$918K	Hold	13,758	–	–	0.17%	119
2013 Q3	$863K	Sell	13,758 -800	-5%	-$51.5K	0.18%	120
2013 Q2	$910K	Buy	+14,558	New	+$924K	0.2%	108

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Gerald L. Ray & Associates's GSK Position: Q3 2017 in Review

Gerald L. Ray & Associates reduced its GSK (GSK) stake by 19% in Q3 2017, selling an estimated $87.3K and leaving 7,334 shares worth $372K. The position accounts for 0.05% of the portfolio, ranked #254.

Gerald L. Ray & Associates first reported a position in GSK in Q2 2013 and has held it in 18 quarters since. The position peaked at $1.07M in Q1 2015. 741 funds tracked by Wall St. Rank hold GSK as of Q3 2017.

Gerald L. Ray & Associates held 7,334 shares of GSK worth $372K as of Q3 2017.
Gerald L. Ray & Associates sold 1,720 GSK shares in Q3 2017, an estimated $87.3K.
GSK made up 0.05% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #254 holding.
Gerald L. Ray & Associates first reported a position in GSK in Q2 2013 and has held it in 18 quarters since.
Gerald L. Ray & Associates's GSK position peaked at $1.07M in Q1 2015.
741 funds tracked by Wall St. Rank held GSK as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.